NCT07409844 2026-02-20
RESET C2
Zealand University Hospital
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT06093425 2025-12-17
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 3 Not yet recruiting
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT06400160 2025-11-25
Clinical Trial of TB511 in Advanced Solid Tumors
Twinpig Biolab, Inc.
Phase 1/2 Not yet recruiting
NCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT04901741 2025-06-27
OPTIMUS
TME Pharma AG
Phase 2 Not yet recruiting
NCT06646445 2025-06-13
PREMICES
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT06923475 2025-04-11
NEODISCO
Amsterdam UMC, location VUmc
Phase 2/3 Not yet recruiting
NCT06484153 2024-07-03
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting
NCT06411171 2024-05-17
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Xijing Hospital of Digestive Diseases
Phase 3 Not yet recruiting
NCT05909423 2023-06-18
FLU-IMMUNE
Zealand University Hospital
Phase 2 Not yet recruiting